---
layout: default
title: Azelastine Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 56
evidence_level: L5
indication_count: 0
---

# Azelastine Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Azelastine Hydrochloride: Drug Repurposing Assessment — Insufficient Data for Prediction

## One-Sentence Summary

Azelastine Hydrochloride is a second-generation antihistamine known for its use in allergic rhinitis and allergic conjunctivitis. This Evidence Pack contains **no TxGNN-predicted new indications**, and two unresolved data gaps — including a **Blocking**-severity gap on safety data — prevent a complete repurposing evaluation. The overall assessment is currently classified as **Hold** pending remediation of these critical gaps.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in Evidence Pack |
| Predicted New Indication | None — no TxGNN predictions generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not applicable |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

---

## South Africa Market Information

Azelastine Hydrochloride is currently **not registered with SAHPRA** and holds no active product licences in South Africa. There are no approved dosage forms, brand names, or indications on record.

If registration is being considered, a full SAHPRA submission — including a locally relevant Professional Information (PI) document, safety data, and clinical evidence package — would be required.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA via the MedSafety reporting system.

> **Note:** Two data gaps affecting safety assessment remain unresolved:
> - **DG001 (Blocking):** PI warnings and contraindications have not been retrieved. This gap prevents an S1 safety pre-screening and must be resolved before any repurposing evaluation can proceed.
> - **DG002 (High):** Mechanism of action data is unavailable, limiting mechanistic plausibility analysis for any future predicted indication.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Azelastine Hydrochloride is critically incomplete — no TxGNN-predicted indications were generated, a Blocking-severity data gap on safety information remains open, and the drug has no SAHPRA registration history. No repurposing pathway can be assessed until these issues are resolved.

**To proceed, the following is needed:**

- **Resolve DG001 (Blocking — highest priority):** Retrieve SAHPRA PI warnings and contraindications by downloading and parsing the applicable Professional Information PDF; re-run the S1 safety pre-screening
- **Resolve DG002 (High):** Query the DrugBank API to obtain the mechanism of action; this will enable mechanistic plausibility analysis for any predicted indications
- **Confirm DrugBank ID:** The DrugBank ID is currently `null`; resolving this is required to unlock downstream drug–disease mapping and evidence collection pipelines
- **Re-run TxGNN prediction model:** Once the DrugBank ID is confirmed and drug metadata is complete, re-run the TxGNN model to generate candidate repurposing predictions
- **Conduct a full evidence collection pass:** Once predictions are available, trigger clinical trial (ClinicalTrials.gov, SANCTR, PACTR) and literature (PubMed) searches for the top-ranked indication
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

